

References

I-9271

1. Roctavian Prescribing Information. BioMarin Pharmaceutical Inc. June 2023.
2. Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. *N Engl J Med* 2020; 382:29-40.
3. Medical and Scientific Advisory Committee. MASAC Document Regarding Risks of Gene Therapy Trials for Hemophilia. Document #254. December 2018.
4. Pipe Steven, VandenDriessche T, Pasi J, Miesbach W. Moving Beyond Factor: Shifting the Paradigm in Hemophilia Through Gene Therapy. Medscape Education Series. Presented through a collaboration between the National Hemophilia Foundation and Medscape. December 2019. Accessed at <https://www.medscape.org/viewarticle/922905>
5. World Health Organization (WHO) Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations. 2016 update.
6. World Health Organization (WHO) Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach – Second edition. June 2016.
7. Valoctogene roxaparvovec clinical data presented at the Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Melbourne, Australia; 6-10 July 2019. (pre-approval information).
8. National Hemophilia Foundation. Bleeding Disorders A-Z/ Types/ Hemophilia-A. Accessed at <https://www.hemophilia.org/bleeding-disorders-a-z/types/hemophilia-a>
9. National Hemophilia Foundation. One Size Does Not Fit All: Individualized Therapy. Dr Steven Pipe. September 2016. Accessed at <https://www.hemophilia.org/educational-programs/education/online-education/one-size-does-not-fit-all-individualized-therapy>
10. CDC Centers for Disease Control and Prevention. Inhibitors and Hemophilia. Accessed at <https://www.cdc.gov/ncbddd/hemophilia/inhibitors.html>

11. Srivastave A, Santagostino E, Dougall A, et al. World Federation of Hemophilia Guidelines for the Management of Hemophilia. 3rd edition. August 2020.